Smoking‐related changes in the background lung of specimens resected for lung cancer: a semiquantitative study with correlation to postoperative course

Kawabata, Yoshinori; Hoshi, Eishin; Murai, Katsumi; Ikeya, Tomohiko; Takahashi, Nobumasa; Saitou, Yasuki; Kurashima, Kazuyoshi; Ubukata, Mikio; Takayanagi, Noboru; Sugita, Hironobu; Kanauchi, S; Colby, Thomas V.

doi:10.1111/j.1365-2559.2008.03183.x

Cited by 142 publications

(147 citation statements)

References 25 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…All tumors were classified according to standard histopathological criteria. 44 Histological evaluation of the frozen tumor tissues showed that on average, all specimens studied consisted of 68% ± 15% tumor cells. Adjacent non-neoplastic tissues were used as control tissues for the expression studies.…”

Section: Methodsmentioning

confidence: 99%

Human Oncoprotein MDM2 Up-regulates Expression of NF- B2 Precursor p100 Conferring a Survival Advantage to Lung Cells

Vaughan

Mohanraj

Singh³

et al. 2011

Genes & Cancer

View full text Add to dashboard Cite

The current model predicts that MDM2 is primarily overexpressed in cancers with wild-type (WT) p53 and contributes to oncogenesis by degrading p53. Following a correlated expression of MDM2 and NF-κB2 transcripts in human lung tumors, we have identified a novel transactivation function of MDM2. Here, we report that in human lung tumors, overexpression of MDM2 was found in approximately 30% of cases irrespective of their p53 status, and expression of MDM2 and NF-κB2 transcripts showed a highly significant statistical correlation in tumors with WT p53. We investigated the significance of this correlated expression in terms of mechanism and biological function. Increase in MDM2 expression from its own promoter in transgenic mice remarkably enhanced expression of NF-κB2 compared with its non-transgenic littermates. Knockdown or elimination of endogenous MDM2 expression in cultured non-transformed or lung tumor cells drastically reduced expression of NF-κB2 transcripts, suggesting a normal physiological role of MDM2 in regulating NF-κB2 transcription. MDM2 could up-regulate expression of NF-κB2 transcripts when its p53-interaction domain was blocked with Nutlin-3, indicating that the MDM2-p53 interaction is dispensable for up-regulation of NF-κB2 expression. Consistently, analysis of functional domains of MDM2 indicated that although the p53-interaction domain of MDM2 contributes to the up-regulation of the NFκB2 promoter, MDM2 does not require direct interactions with p53 for this function. Accordingly, MDM2 overexpression in non-transformed or lung cancer cells devoid of p53 also generated a significant increase in the expression of NF-κB2 transcript and its targets CXCL-1 and CXCL-10, whereas elimination of MDM2 expression had the opposite effects. MDM2-mediated increase in p100/NF-κB2 expression reduced cell death mediated by paclitaxel. Furthermore, knockdown of NF-κB2 expression retarded cell proliferation. Based on these data, we propose that MDM2-mediated NF-κB2 up-regulation is a combined effect of p53-dependent and independent mechanisms and that it confers a survival advantage to lung cancer cells.

show abstract

Section: Methodsmentioning

confidence: 99%

Human Oncoprotein MDM2 Up-regulates Expression of NF- B2 Precursor p100 Conferring a Survival Advantage to Lung Cells

Vaughan

Mohanraj

Singh³

et al. 2011

Genes & Cancer

View full text Add to dashboard Cite

show abstract

“…(45) encontraron que el 70% de los pacientes que desarrollaron síndrome de dificultad respiratoria poslobectomía (por cáncer de pulmón) presentaron patrón histológico de combinación de fibrosis pulmonar y enfisema. Otros trabajos describen mayor incidencia de falla respiratoria y reintubación en estos pacientes (17%) (46).…”

Section: Pronósticounclassified

Combinación de fibrosis pulmonar y enfisema: una entidad poco reconocida

Carrillo¹,

Morales-Cárdenas

Arias³

et al. 2016

rev. colomb. neumol.

View full text Add to dashboard Cite

Objetivo : revisar definición, fisiopatología, manifestaciones clínicas, alteraciones enestudios de imágenes, pruebas de función pulmonar y pronóstico de los pacientes con combinaciónde fibrosis pulmonar y enfisema.Método : se realizó una revisión de la literatura en PubMed, para lo cual se usaron lostérminos MeSH: “fibrosis pulmonar”, “enfisema pulmonar” y la palabra “combinación”, limitandola búsqueda a la literatura publicada en los últimos cinco años. Para ilustrar la revisión seescogieron casos representativos de combinación de fibrosis pulmonar y enfisema estudiados ennuestra institución.Resultados : la búsqueda arrojó 163 referencias con los criterios seleccionados, se revisaron46 artículos en inglés, francés y español que se consideraron relevantes para el cumplimientodel objetivo de la revisión.Conclusiones: el término de combinación de fibrosis pulmonar y enfisema se refiere a la evidencia de enfisema y fibrosis en patología o en estudios de tomografía computarizada de alta resolución (tomografía computarizada de alta resolución). Inicialmente se describió en pacientes con patrón de neumonía intersticial usual y enfisema; sin embargo, se describe la coexistencia de fibrosis pulmonar y enfisema en pacientes con patrones de fibrosis pulmonar diferentes al de la neumonía intersticial usual. Los pacientes con combinación de fibrosis pulmonar y enfisema comparten antecedentes, manifestaciones clínicas, alteraciones radiológicas y pruebas de función pulmonar características, que difieren del grupo de pacientes con fibrosis pulmonar sin enfisema y aquellos con enfisema sin fibrosis. La morbimortalidad de aquellos con combinación de fibrosis pulmonar y enfisema difiere de la de los pacientes con enfisema o fibrosis pulmonar idiopática. Las opciones terapéuticas son limitadas.

show abstract

“…9 However, studies based on lung cancer resection specimens have shown that fine fibrosis in the alveolar walls around respiratory bronchioles is in fact very common in the lungs of cigarette smokers who have no clinical evidence of an ILD. 2,3,5 Further, Wright et al 10 found that, in fact, in most smokers fibrosis in the walls of bronchioles actually correlates with physiologic abnormalities of airflow obstruction rather than with the restrictive profile typical of most ILDs. Thus, the extent of fibrosis in or around the bronchiolar wall does not appear to be a useful criterion for separating RB and RBILD, and most authors make the distinction on the presence or absence of clinical features of an ILD.…”

Section: Respiratory Bronchiolitis and Rbildmentioning

confidence: 99%

“…This lesion has been referred to by various names, including respiratory bronchiolitis-interstitial lung disease with fibrosis, 1 airspace enlargement with fibrosis, 2 and smoking-related interstitial fibrosis. 3 We have suggested that, to avoid confusion with other forms of smoking-related interstitial lung disease (ILD), the lesion be referred to as respiratory bronchiolitis with fibrosis (RBF).…”

mentioning

confidence: 99%

Respiratory Bronchiolitis With Fibrosis–Interstitial Lung Disease: A New Form of Smoking-Induced Interstitial Lung Disease

Churg

Hall

Bilawich

2014

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Smoking‐related changes in the background lung of specimens resected for lung cancer: a semiquantitative study with correlation to postoperative course

Abstract: AEF is an important smoking-related change in the lung that appears to correlate with the smoking history, and its distinction from UIP/P may be important.

Cited by 142 publications

References 25 publications

Human Oncoprotein MDM2 Up-regulates Expression of NF- B2 Precursor p100 Conferring a Survival Advantage to Lung Cells

Human Oncoprotein MDM2 Up-regulates Expression of NF- B2 Precursor p100 Conferring a Survival Advantage to Lung Cells

Combinación de fibrosis pulmonar y enfisema: una entidad poco reconocida

Respiratory Bronchiolitis With Fibrosis–Interstitial Lung Disease: A New Form of Smoking-Induced Interstitial Lung Disease

Contact Info

Product

Resources

About